Concepedia

Author

Dilara McCauley

Karyopharm Therapeutics (United States)

Also Known As

D L McCauley, D McCauley, D. McCauley, D. Mccauley, Dilara McCauley

148

Publications

2.8K

Citations

25

H-Index

45

Concepts

All Affiliations

Karyopharm Therapeutics (United States)The Ohio State UniversityPrincess Margaret Cancer CentreDana-Farber Cancer InstituteRigshospitalet
DM

About

Dilara McCauley is an author at Karyopharm Therapeutics (United States) specializing in medicine, cell biology, and cancer research.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

10

10

656

2

Cell Biology

8

8

605

3

Immunology

4

4

234

4

Health Sciences

1

1

71

5

Biochemistry

1

1

37

Dilara McCauley

×

26

Publications

2.4K

Citations

24

H-Index

YearCitations

Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia

Rosa Lapalombella, Qingxiang Sun, Katie Williams,

Blood

2012

293

First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors

Albiruni R. Abdul Razak, Morten Mau‐Sørensen, Nashat Gabrail,

Journal of Clinical Oncology

2016

244

Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells

Julia Etchin, Qingxiang Sun, Alex Kentsis,

Leukemia

2012

190

<scp>KPT</scp>‐330 inhibitor of <scp>CRM</scp>1 (<scp>XPO</scp>1)‐mediated nuclear export has selective anti‐leukaemic activity in preclinical models of <scp>T</scp>‐cell acute lymphoblastic leukaemia and acute myeloid leukaemia

Julia Etchin, Takaomi Sanda, Marc R. Mansour,

British Journal of Haematology

2013

173

Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276

Jessica Schmidt, Esteban Braggio, K. Martin Kortuem,

Leukemia

2013

161

Sequential Loss of Tumor Vessel Pericytes and Endothelial Cells after Inhibition of Platelet-Derived Growth Factor B by Selective Aptamer AX102

Barbara Sennino, Beverly L. Falcón, Dilara McCauley,

Cancer Research

2007

153

Verdinexor, a Novel Selective Inhibitor of Nuclear Export, Reduces Influenza A Virus Replication<i>In Vitro</i>and<i>In Vivo</i>

Olivia Perwitasari, Scott K. Johnson, Xiuzhen Yan,

Journal of Virology

2014

113

Preclinical Evaluation of the Novel, Orally Bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in Spontaneous Canine Cancer: Results of a Phase I Study

Cheryl A. London, Luis Feo Bernabé, Sandra Barnard,

PLoS ONE

2014

101

XPO1 (CRM1) Inhibition Represses STAT3 Activation to Drive a Survivin-Dependent Oncogenic Switch in Triple-Negative Breast Cancer

Yan Cheng, Michael P. Holloway, Kevin T. Nguyen,

Molecular Cancer Therapeutics

2014

101

Nuclear export inhibitors avert progression in preclinical models of inflammatory demyelination

Jeffery D. Haines, Olivier Herbin, Belén de la Hera,

Nature Neuroscience

2015

94

Page 1